With the payment, all conditions for completion of the transaction have been fulfilled, and the initial transaction has been completed. The total upfront payment of USD 12 million comprises a USD 7 million cash licence payment and a USD 5 million direct investment in AlzeCure. In addition to the upfront payment, the agreement with QuantumCell includes development and commercial milestone payments, as well as tiered royalties ranging from high single-digit to low double-digit percentages on future sales. "The receipt of the upfront payment and completion of the transaction with QuantumCell is a clear testament to the strength of our research and the value represented by NeuroRestore. For more information, visit www.alzecurepharma.comImage AttachmentsMartin Jönsson CEO AlzeCure PharmaAttachmentsAlzeCure receives a total upfront payment of USD 12 million and completes the initial transaction with QuantumCellSOURCE: AlzeCure PharmaView the original press release on ACCESS Newswire:https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/alzecure-receives-a-total-upfront-payment-of-usd-12-million-and-compl-1206415